Abstract Library

#4644 First results of peptide-receptor radionuclide therapy in the Russian population of patients with neuroendocrine neoplasms

Introduction: Peptide-receptor radionuclide therapy (PRRT) has demonstrated its efficacy and safety in a number of clinical trials and has become widely used in the treatment of patients with neuroendocrine neoplasms (NEN) expressing somatostatin receptors.

Conference:

Presenting Author: Baranova O

Authors: Baranova O, Geliashvili T, Markovich A, Zhulikov Y, Evdokimova E,

Keywords: NET, PRRT, 177Lu-DOTATATE,

#4424 Tumour-derived apolipoprotein E induces tip endothelial cell to remodel tumour stroma ratio and promote pancreatic neuroendocrine tumour progression

Introduction: Current clinical trials have shown that single-targeted matrix administration does not improve patient prognosis. The investigation of targeted matrix administration in combination with other therapies is crucial for effectively managing TSR in pNETs.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: APOE, pancreatic neuroendocrine tumour, endothelial cell, tumour stroma ratio, mTOR inhibitor,

#4386 Streptozotocin- and temozolomide-based chemotherapy treatment in neuroendocrine neoplasms – Efficacy in patients treated outside clinical trials

Introduction: Chemotherapy treatment based on alkylating agents is useful in pancreatic and grade 3 neuroendocrine neoplasms (NENs). However, no current real-life data is available comparing streptozotocin (STZ) and temozolomide (TEM) combinations.

Conference:

Presenting Author: García-Álvarez A

Authors: García Alvarez A, Martínez-Badal S, García-Burillo A, Simó Perdigo M, Merino Casabiel X,

Keywords: Streptozotocin, temozolomide, neuroendocrine neoplasm,

#4352 What can a reference centre offer to patients? Evolution of first visits for neuroendocrine and endocrine tumours and its relation to clinical trials availability.

Introduction: Endocrine and neuroendocrine neoplasia (NEN), which include gastroenteropancreatic neuroendocrine tumours, thyroid cancer and adrenal carcinoma, have a low incidence, making their diagnosis and treatment difficult. Due to this complexity, patients should be managed at specialised centres; however, the lack of official referral networks complicates the concentration of cases.

Conference:

Presenting Author: Martinez-Badal S

Authors: Martínez-Badal S, Hernando Cubero J, García Alvarez A, Elguero B, Alcantara A,

Keywords: Neuroendocrine, Clinical Trial, Reference Centre, Patient referral,

#4333 Clinical efficacy of peptide receptor radionuclide therapy with radiolabelled somatostatin analogues (PRRT) of metastatic neuroendocrine tumours (NETs) – A single-centre cohort study

Introduction: PRRT is indicated for disease progression in patients with disseminated or unresectable NETs, especially those originating from the midgut. Up to date clinical trials have proven the efficacy of PRRT in gastrointestinal NETs, while data on other localisations are limited.

Conference:

Presenting Author:

Authors: Hamm M, Kropinska A, Handkiewicz-Junak D, Ledwon A, Paliczka-Cieslik E,

Keywords: PRRT, NET, gastrointestinal, pancreatic, bronchopulmonary, FPI,